Nucleic Acid, Nucleoside, or Nucleotide – Page 17

Actionable Insights Powered by AI

Boundless Bio, Oncology Startup Targeting Extrachromosomal DNA, Files for $100 Million IPO

2 years ago talkbio0Tagged Arch of foot, Backed, Bayer, bleomycin/dacarbazine/lomustine/vincristine, Boundless, Checkpoint Kinase 1 Inhibitors, extrachromosomal DNA, IPO, Nasdaq Listing, Oncology Startup, Partner in relationship, Phase 1 Trials, Preliminary, Public Offering, Second Half of 2024, small molecule drugs, symbol

Boundless Bio, Oncology Startup, Initial Public Offering (IPO), Extrachromosomal DNA (ecDNA), Small Molecule Drugs (ecDTx), Checkpoint Kinase 1 Inhibitors, Phase 1 Trials, Nasdaq Listing (Symbol: BOLD), Backed by Bayer and Arch Venture Partners, Preliminary Data Expected in Second Half of 2024

Takeda Appoints Former CRISPR CMO Phuong Khanh (PK) Morrow to Lead Oncology R&D Amidst Pipeline Pruning

2 years ago talkbio0Tagged Clustered Regularly Interspaced Short Palindromic Repeats, PK

Clustered Regularly Interspaced Short Palindromic Repeats, PK